These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21251627)

  • 21. Another small step for small vessels.
    Morrison DA
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):67-9. PubMed ID: 20578195
    [No Abstract]   [Full Text] [Related]  

  • 22. A generation 2.5 drug-eluting stent?
    Ellis SG
    JACC Cardiovasc Interv; 2009 Oct; 2(10):986-8. PubMed ID: 19850259
    [No Abstract]   [Full Text] [Related]  

  • 23. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.
    Kukreja N; Onuma Y; Garcia-Garcia HM; Daemen J; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jun; 2(6):534-41. PubMed ID: 19539258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing the impact of primary percutaneous coronary intervention in acute myocardial infarction.
    Satler LF
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):201. PubMed ID: 21290554
    [No Abstract]   [Full Text] [Related]  

  • 25. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
    Leon MB; Allocco DJ; Dawkins KD; Baim DS
    JACC Cardiovasc Interv; 2009 Jun; 2(6):504-12. PubMed ID: 19539253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE
    EuroIntervention; 2012 May; 8(1):117-9. PubMed ID: 22580255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Let it be, let it be.
    Butman SM
    Catheter Cardiovasc Interv; 2009 Jun; 73(7):898. PubMed ID: 19455656
    [No Abstract]   [Full Text] [Related]  

  • 28. High glycemic stenting menu.
    Hillegass WB
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):934-5. PubMed ID: 21108370
    [No Abstract]   [Full Text] [Related]  

  • 29. Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry.
    Costa JR; Sousa A; Moreira AC; Costa RA; Cano M; Maldonado G; Campos C; Carballo M; Pavanello R; Sousa JE
    JACC Cardiovasc Interv; 2010 Jan; 3(1):12-8. PubMed ID: 20129562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction.
    Slottow TL; Steinberg DH; Roy P; Javaid A; Buch AN; Okabe T; Xue Z; Smith K; Torguson R; Pichard AD; Satler LF; Suddath WO; Kent KM; Waksman R
    Cardiovasc Revasc Med; 2008; 9(1):24-8. PubMed ID: 18206634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
    JACC Cardiovasc Interv; 2011 Mar; 4(3):310-6. PubMed ID: 21435609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The process of bringing new drug-eluting stents to market will they see the light of day?
    Holmes DR; Patel M
    JACC Cardiovasc Interv; 2008 Oct; 1(5):533-4. PubMed ID: 19463355
    [No Abstract]   [Full Text] [Related]  

  • 33. Does angiographic response to wiring of totally occluded vessels predict outcomes in ST-segment elevation myocardial infarction?
    Ambrose JA; Buhari CF
    JACC Cardiovasc Interv; 2011 Jan; 4(1):63-5. PubMed ID: 21251630
    [No Abstract]   [Full Text] [Related]  

  • 34. Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion.
    Tcheng JE; Zidar DA
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1266-8. PubMed ID: 20129554
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of the First In Man experience with everolimus-eluting stents.
    Kimmelstiel C
    Catheter Cardiovasc Interv; 2010 Jun; 75(7):1004-5. PubMed ID: 20517960
    [No Abstract]   [Full Text] [Related]  

  • 37. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.
    Jensen LO; Tilsted HH; Thayssen P; Kaltoft A; Maeng M; Lassen JF; Hansen KN; Madsen M; Ravkilde J; Johnsen SP; Sørensen HT; Thuesen L
    EuroIntervention; 2010 Apr; 5(8):898-905. PubMed ID: 20542774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
    Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
    JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DES in SVGs: safe and at least short-term effective.
    Hillegass WB
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):356-7. PubMed ID: 21328680
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.